Clinical trials
Cholangitis clinical trials
Below are recruiting cholangitis clinical trials, each written for real people, not researchers. We’re tracking 60 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03146936Recruiting
Study of people with primary sclerosing cholangitis in Switzerland
This study follows people diagnosed with primary sclerosing cholangitis to better understand the condition over time. It may help doctors learn which factors affect health and care, and improve future treatment decisions.
Lugano, Canton TicinoAges Any age - NCT04181138Recruiting
Study of childhood primary sclerosing cholangitis types
This study follows children and young adults with primary sclerosing cholangitis (PSC) to understand the condition and how it shows up on scans or biopsy. It may help doctors better recognize PSC and choose the best next steps for care.
Los Angeles, CaliforniaAges 2–25 - NCT02137668RecruitingPhase 1
Testing vancomycin for certain pediatric bile duct conditions
This early-phase study tests whether the antibiotic vancomycin can help children with primary sclerosing cholangitis or biliary atresia, and related gut/bile duct problems. It may work by changing gut bacteria, but you would need to avoid certain medicines beforehand.
Sacramento, CaliforniaAges 2 weeks–40 years - NCT05919433Recruiting
Program to find people with primary biliary cholangitis
This trial is testing a “find patients who are missing from care” program for people with primary biliary cholangitis (PBC). It may help connect you to follow-up sooner if you’ve been hard to reach through usual clinic records.
Terrassa, BarcelonaAges 18 years+ - NCT05618145Recruiting
Join a national study database for primary sclerosing cholangitis
This study creates a national database for people diagnosed with primary sclerosing cholangitis (PSC). It may help researchers learn more about the condition by collecting health information from participants.
AnconaAges 17 years+ - NCT07667166Recruiting
Measuring outcomes in acute cholangitis
This study looks at how well people recover from acute cholangitis, a serious bile duct infection. It will create a tool to track the impact of treatment, such as drainage procedures, to help doctors improve care.
Hyderabad, TelanganaAges 18–80 - NCT07631442Enrolling by invitation
Digital Health Monitoring for Primary Biliary Cholangitis
This study uses a smartphone app or digital platform to track how you're feeling day-to-day if you have primary biliary cholangitis (PBC), a liver condition where your immune system damages bile ducts. Researchers want to see if this digital monitoring helps them better understand and manage PBC symptoms.
Redwood City, CaliforniaAges 18 years+ - NCT07607353Recruiting
Biodegradable Stents for Primary Sclerosing Cholangitis
This trial tests a new type of stent (a small tube placed in bile ducts) that dissolves on its own over time in patients with primary sclerosing cholangitis (PSC), a rare disease affecting the bile ducts. The goal is to widen narrowed ducts and reduce the need for repeated procedures.
LondonAges 18 years+ - NCT06767605Recruiting
Spanish registry for autoimmune liver diseases
This study collects information from people with autoimmune or cholestatic liver diseases to better understand them and improve care. It does not test a new treatment, but your participation can help future research.
BarcelonaAges 18 years+ - NCT07449793Recruiting
PBC treatment response and long-term health outcomes
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07407491RecruitingPhase 2
Antibiotic during ERCP for bile duct infection
This trial tests if giving an antibiotic directly into the bile duct during an ERCP procedure helps treat acute cholangitis better than standard care. If you have mild or moderate cholangitis and are scheduled for ERCP within 48 hours, you may be a candidate.
Cheras, Kuala LumpurAges 18 years+ - NCT07387549RecruitingPhase 3
Elafibranor for primary sclerosing cholangitis
This study tests a new medication called elafibranor for adults with primary sclerosing cholangitis (PSC), a chronic liver disease. It aims to see if elafibranor can safely help improve liver health when compared to no treatment.
Chandler, ArizonaAges 18–75 - NCT07341282RecruitingPhase 2
Vancomycin for ulcerative colitis with liver condition
This trial tests whether the antibiotic vancomycin can help treat active ulcerative colitis in people who also have primary sclerosing cholangitis (a liver condition). Vancomycin may reduce inflammation in the gut by changing the bacteria in your intestines.
Hamilton, OntarioAges 18 years+ - NCT07229911RecruitingPhase 1
Study of TAK-781 in healthy people and PSC patients
This study tests an investigational drug called TAK-781 in healthy volunteers and in people with primary sclerosing cholangitis (PSC) who do not have cirrhosis. The study aims to see how the drug is processed by the body and whether it is safe.
Salt Lake City, UtahAges 18–68 - NCT07216235RecruitingPhase 3
Long-term study of saroglitazar for PBC with cirrhosis
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Marietta, GeorgiaAges 18 years+ - NCT07205874Recruiting
Finding PBC early in people with positive AMA
This study looks for early signs of Primary Biliary Cholangitis in people who have a positive AMA blood test but normal liver enzyme levels. It aims to find the disease before it causes symptoms.
MadridAges 18–80 - NCT07161245Recruiting
Fatigue relief study for primary biliary cholangitis
This trial tests a program of exercise, nutrition, and education to help reduce fatigue in people with primary biliary cholangitis. It aims to see if this program can improve energy and quality of life.
Barcelona, BarcelonaAges 18–80 - NCT05295680RecruitingPhase 2
Oral hymecromone for primary sclerosing cholangitis
This trial tests whether taking hymecromone by mouth can improve primary sclerosing cholangitis (a liver/bile duct condition). It may help by targeting inflammation and bile duct problems, especially in people who are stable on other medicines.
Redwood City, CaliforniaAges 14–75 - NCT06905054RecruitingPhase 2
Preventing PSC recurrence after liver transplant
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
Scottsdale, ArizonaAges 18–75 - NCT06365424RecruitingPhase 2/Phase 3
Fenofibrate for Primary Biliary Cholangitis (PBC)
This trial tests whether the drug fenofibrate can help people with primary biliary cholangitis (PBC), a chronic liver disease. It is for patients who have already taken fenofibrate in a previous study and want to continue treatment.
Xi'an, ShaanxiAges 18–75 - NCT05151809Recruiting
Italy-wide database study for adults with primary biliary cholangitis
This study creates a national registry (database) of adults in Italy living with primary biliary cholangitis (PBC). Being included can help doctors better understand the condition and improve future care.
AnconaAges 18 years+ - NCT05876182RecruitingPhase 2
Vancomycin for primary sclerosing cholangitis
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
Monza, Monza E BrianzaAges 15–70 - NCT06755151RecruitingPhase 3
Fenofibrate for primary biliary cholangitis: a real-world study
This study tests fenofibrate, a medicine that may help lower liver enzymes in people with primary biliary cholangitis (PBC). It looks at how well the drug works in everyday medical practice.
Xi'an, ShaanxiAges 18–75 - NCT06755541RecruitingPhase 3
Fenofibrate plus ursodeoxycholic acid for PBC: a real-world study
This trial is testing whether adding fenofibrate to the standard PBC medicine ursodeoxycholic acid helps people with primary biliary cholangitis. It's a real-world study, meaning it looks at how treatments work in everyday practice. You can join only if you have already completed an earlier fenofibrate study.
Xi'an, ShaanxiAges 18–75
Hear when a new Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangitis?
- Yes. Clin2 currently lists 60 recruiting cholangitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.